Clinical Edge Journal Scan

Negative FDG‐avid lesions in proximal colon ensure absence of additional lesions other than target CRC


 

Key clinical point: Among patients with stenotic leftsided colorectal cancer (CRC) who underwent incomplete colonoscopy, absence of negative preoperative 18 fluoro2deoxyglucose (FDG) avid lesions in the proximal colon other than the target CRC ensures the absence of additional lesions warranting changes in surgical plan.

Major finding: The cumulative detection rate of advanced adenoma was significantly higher in the incomplete vs complete colonoscopy group at 1 year (6.3% vs 0.7%) and 5 years (12.5% vs 9.9%; P = .012). However, the cumulative rate of detection of adenocarcinoma at 1 and 5 years ( P = .15) and 5-year cumulative rate of additional surgery ( P = .85) were not different between the groups.

Study details: Findings are from an analysis of 754 patients with left sided CRC without synchronous FDG avid lesions on preoperative 18 FDG positron emission tomography/computed tomography. Patients were categorized into those who underwent complete (n=616) and incomplete (n=138) preoperative colonoscopy.

Disclosures: This study was funded by the Korea Institute of Radiological and Medical Sciences, funded by the Ministry of Science and ICT, Republic of Korea. The authors declare no competing interests.

Source: Lee JI et al. Sci Rep. 2021 Jul 19. doi: 10.1038/s41598-021-94030-w .

Recommended Reading

AGA Clinical Practice Update: Expert Review on colonoscopy quality improvement
MDedge Hematology and Oncology
Better to binge drink than regularly tipple, suggests GI cancer study
MDedge Hematology and Oncology
Nivolumab gets additional adjuvant indication for bladder cancer
MDedge Hematology and Oncology
Computer-aided detection system superior to other endoscopic imaging techniques in detecting colorectal neoplasia
MDedge Hematology and Oncology
MSS metastatic CRC: Patients without liver involvement may benefit from PD-1/PD-L1 inhibitors
MDedge Hematology and Oncology
Adding tumor deposits to lymph node metastases count aids prognostication in stage III colon cancer
MDedge Hematology and Oncology
Metastatic CRC: Aflibercept-FOLFIRI is a feasible second-line treatment option
MDedge Hematology and Oncology
High mesothelin expression tied to chemoresistance and poor prognoses in stage IV CRC
MDedge Hematology and Oncology
mCRC: Sequential scheduling of bevacizumab and chemotherapy may help optimize therapeutic efficacy
MDedge Hematology and Oncology
Updated TRICOLORE findings support bevacizumab with S-1 and irinotecan combo as first-line regimen for mCRC
MDedge Hematology and Oncology